Loading...
Pharmaron Beijing Co., Ltd.
3759.HK•HKSE
Healthcare
Biotechnology
HK$20.88
HK$2.06(10.95%)
Hong Kong Market is Open • 11:53Pharmaron Beijing Co., Ltd. (3759.HK) AI-Powered Stock Analysis
See how Pharmaron Beijing Co., Ltd. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerPharmaron Beijing Co., Ltd. (3759.HK) Stock Overall Grade
Pharmaron Beijing Co., Ltd.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Pharmaron Beijing Co., Ltd.'s overall stock rating.
Forecast
B+Score
79/100Financial Growth
BScore
60/100Fundamental Growth
BScore
66/100Key Ratios
B+Score
73/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
95/100Analyst Consensus
C+Score
50/100Pharmaron Beijing Co., Ltd. (3759.HK) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 79/100 (B+), reflecting high confidence in its potential. Financial Growth (60/100, B) and Fundamental Growth (66/100, B) highlight its stability, while Key Ratios (73/100, B+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (95/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Pharmaron Beijing Co., Ltd. stock grade, including financials, comparisons, and forecasts.